Literature DB >> 8098992

Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.

U Srinivas1, E Tagliabue, M Campiglio, S Ménard, M I Colnaghi.   

Abstract

In the present study we utilized two previously described monoclonal antibodies (mAb), and their respective Fab portions, directed against the extracellular domain of p185HER2, a transmembrane glycoprotein with intrinsic tyrosine kinase activity coded by the HER2/neu oncogene, to study the mechanism of mAb-induced receptor internalization and phosphorylation. Fluorescence scan analysis and direct binding of radiolabelled mAb and their Fab fragments showed that entire MGR2 and MGR3 mAb were reactive with similar binding affinity on two cell lines (Calu-3 and Sk-Br-3) overexpressing the p185HER2 receptor, and unreactive on unrelated cells. The corresponding Fab fragments were positive on the related cells, but bound with diminished intensity and affinity. Entire MGR2 and MGR3 induced internalization in both Calu-3 and Sk-Br-3 cells, whereas their Fab portions were not internalized. When the bivalency of the MGR2 Fab fragment was artificially reconstituted by incubation with rabbit anti-(mouse IgG), internalization was obtained. Monovalent binding of the entire labelled antibodies, obtained in the presence of a saturating amont of unlabelled antibody, decreased both the rate and the final amount of internalized antibody. Metabolic labelling and immunoblotting experiments showed that incubation with entire MGR3 amplified the basal phosphorylation of the p185HER2 receptor in Calu-3 and Sk-Br-3 cells, whereas MGR3 Fab decreased the signal. Taken together, our data indicate that antibody-mediated activation of p185HER2 in Calu-3 and Sk-Br-3 cells occurs through the dimerization of receptor molecules and that bivalency of the activating antibody is mandatory for induction of internalization and phosphorylation of the receptor. Our data support an allosteric model of activation for the p185HER2 receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098992     DOI: 10.1007/bf01742256

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.

Authors:  H Sunada; B E Magun; J Mendelsohn; C L MacLeod
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

2.  Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation.

Authors:  Y Yarden; J Schlessinger
Journal:  Biochemistry       Date:  1987-03-10       Impact factor: 3.162

3.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.

Authors:  R Lupu; R Colomer; G Zugmaier; J Sarup; M Shepard; D Slamon; M E Lippman
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

4.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

5.  Antibody-induced activation of the epidermal growth factor receptor tyrosine kinase requires the presence of detergent.

Authors:  M Spaargaren; L H Defize; S W de Laat; J Boonstra
Journal:  Biochem Biophys Res Commun       Date:  1990-09-14       Impact factor: 3.575

6.  Antibody-induced dimerization activates the epidermal growth factor receptor tyrosine kinase.

Authors:  M Spaargaren; L H Defize; J Boonstra; S W de Laat
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

7.  Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor.

Authors:  A B Schreiber; I Lax; Y Yarden; Z Eshhar; J Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

8.  Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active.

Authors:  Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

9.  Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell.

Authors:  E Roosnek; A Lanzavecchia
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.

Authors:  D F Stern; M P Kamps
Journal:  EMBO J       Date:  1988-04       Impact factor: 11.598

View more
  3 in total

1.  Tailoring subtractive cell biopanning to identify diffuse gastric adenocarcinoma-associated antigens via human scFv antibodies.

Authors:  Tayebeh Mehdipour; Mohammad R Tohidkia; Amir Ata Saei; Amir Kazemi; Shirin Khajeh; Ali A Rahim Rahimi; Sepideh Nikfarjam; Mehrdad Farhadi; Monireh Halimi; Ramin Soleimani; Roman A Zubarev; Mohammad Nouri
Journal:  Immunology       Date:  2019-11-08       Impact factor: 7.397

Review 2.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

Review 3.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.